1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
CK Life Sciences Int'l., (Holdings) Inc.

CK Life Sciences Int'l., (Holdings) Inc.

0775.HK
CK Life Sciences Int'l., (Holdings) Inc.HK flagHong Kong Stock Exchange
0.69
HKD
-0.01
- -
6.63BMarket Cap
CK Life Sciences Int'l., (Holdings) Inc.
0775.HK
(Hong Kong Stock Exchange)

Recent

price

0.69

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.28
0.37
0.47
0.52
0.52
0.51
0.51
0.49
0.54
0.52
0.51
0.56
0.55
0.55
0.57
0.56
Revenue per Share
0.02
0.01
0.02
0.02
0.03
0.02
0.03
0.03
0.03
0.02
0.01
0.02
0.01
- -
-0.01
-0.02
Basic EPS, GAAP
- -
- -
0.04
0.01
0.02
- -
0.02
- -
-0.01
0.02
0.02
0.02
0.02
0.02
0.02
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
- -
- -
Dividend per Share
0.1
0.11
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.31
0.33
0.34
0.34
0.33
0.3
Book Value per Share
0.17
0.16
0.15
0.12
0.11
0.07
0.09
0.12
0.09
0.06
0.1
0.09
0.06
0.06
0.01
0.05
Tangible Book Value per Share
9,611
9,611
9,611
9,611
9,611
9,611
9,611
9,611
9,611
9,611
9,611
9,611
9,611
9,611
9,611
9,611
Basic Weighted Avg Shares
2,694
3,512
4,545
4,971
4,954
4,919
4,869
4,693
5,233
4,967
4,943
5,402
5,276
5,323
5,523
5,410
Sales/Revenue/Turnover
25.29
7.41
8.77
6.46
6.27
5.66
6.51
3.23
7.31
5.63
1.71
4.46
4.59
4.21
1.4
-2.42
Operating Margin (%)
95
102
104
136
136
155
135
145
138
204
220
247
231
234
245
245
Depreciation Expense
209
126
176
229
264
219
253
258
263
182
125
163
132
17
-127
-187
Net Income, GAAP
11.41
28.66
34.21
22.78
15.06
25.42
26.22
14.98
28.62
12.64
- -
31.66
35.59
74.85
- -
- -
Effective Tax Rate (%)
7.74
3.58
3.88
4.61
5.32
4.45
5.2
5.51
5.03
3.66
2.53
3.01
2.5
0.32
-2.29
-3.45
Profit Margin (%)
473
1,263
1,252
671
1,858
474
-1,216
1,190
1,309
-529
2,376
1,094
-937
892
652
-461
Working Capital
37
2,229
2,357
2,761
4,229
2,760
925
3,403
3,893
2,773
6,117
4,920
2,820
4,709
4,749
4,173
LT Debt
5,622
5,633
5,724
5,200
4,875
4,209
4,403
4,757
4,420
4,175
4,718
4,501
4,155
4,189
3,512
3,846
Total Equity
9.27
2.53
3.24
2.87
2.88
2.34
2.75
1.44
2.92
2.55
- -
1.52
1.49
0.56
- -
- -
Return on Invested Capital (%)
11.19
6.98
5.85
7
6.62
6.09
5.93
5.84
5.47
4.99
- -
2.48
2.55
1.07
- -
- -
Return on Capital (%)
24.63
12.4
17.3
23.83
27.42
22.77
26.32
26.89
27.36
18.91
6.35
5.31
4.11
0.52
-3.91
-6.12
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.51%
-3.62%
9.53%
Free Cash Flow
-45.17%
-22.22%
-139.58%
Net Income, GAAP
-90.44%
-172.38%
47.61%
Sales/Revenue/Turnover
1.09%
1.91%
-2.04%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
5,323
2024
- -
- -
- -
- -
5,523
2025
- -
- -
- -
- -
5,410

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
-0.02

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.01
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
CSL Limited (CMXHF)
Hoth Therapeutics, Inc. (HOTH)
MYND Life Sciences Inc. (MYNDF)
Panacos Pharmaceuticals, Inc. (PANC)
Anhui Huaheng Biotechnology Co., Ltd. (688639.SS)
Noile-Immune Biotech Inc. (4893.T)
Business
CK Life Sciences International (Holdings) Inc. is a biotechnology company engaged in research and development, manufacturing, commercialization, marketing, and sale of products in the pharmaceuticals, nutraceuticals, and agriculture-related sectors. Its core product offerings include cancer therapeutics, health supplements, natural healthcare products, eco-fertilizers, and crop protection products. The company focuses on human health and environmental sustainability with operations spanning North America, Asia Pacific, and other regions including Australia, Canada, New Zealand, China, Hong Kong, the United States, and the Virgin Islands. It is headquartered in Hong Kong and was founded in 2001. CK Life Sciences operates through two main segments: Agriculture-Related and Health, with nutraceuticals contributing significantly to its revenue. Recent major changes include a strategic transaction completed in 2024 involving the sale of 100% membership interests in its subsidiary related to cancer treatment, valued at around US$125 million initially with potential additional milestone payments. This transaction combines its cancer therapeutic business with a Nasdaq-listed purchaser to advance the development and commercialization of seviprotimut-L, a melanoma vaccine. Additionally, CK Life Sciences executed a merger between its Canadian drug development arm WEX Pharmaceuticals and Nasdaq-listed Virios Therapeutics, valued at approximately US$100 million via stock exchange, creating a new entity named Dogwood Therapeutics. This move aims to strengthen its presence in the biotech sector and expand access to U.S. capital markets to support clinical trials and R&D, including for products targeting cancer pain and post-viral syndromes. The company has also been involved in collaborations incorporating artificial intelligence for cancer vaccine development, partnering with Shenzhen-based AI drug discovery firm Xtalpi to enhance its tumor vaccine and diagnostic platforms. CK Life Sciences is a subsidiary of CK Hutchison Holdings and is listed on the Hong Kong Stock Exchange under the ticker 0775.HK. These developments reflect CK Life Sciences' ongoing strategic focus on oncology, innovative therapeutics, agricultural sustainability products, and expansion in global markets. Its leadership under Victor Li supports its mission to improve quality of life through biotechnology innovation and sustainable agriculture solutions.